Home World News Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously... World News Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC By Ogkologos - June 30, 2026 243 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the HARMONi-6 study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR Patients with Early Stage NSCLC Have a Higher TMB in Comparison... October 9, 2020 Arsenic Trioxide in Combination with All-Trans Retinoic Acid for the Treatment... September 3, 2025 A new year of expanding research horizons January 21, 2022 24% of Breast Cancers Diagnosed Between Mammograms Could Have Been Detected... May 10, 2021 Load more HOT NEWS Jaw Problems Linked to Bone-Modifying Drugs Not as Rare as Once... Entrectinib Is Effective and Well Tolerated in Patients with Treatment-Naïve ROS1-positive... Teclistamab Results in a High Rate of Deep and Durable Response... FDA Approves Liquid Biopsy NGS Companion Diagnostic Test for Multiple Cancers...
